Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A

NCT00543439 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00543439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00543439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
April 30, 2018
Enrollment
66 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a